Reply to “Contradictory Results with High-Dosage Rifamycin in Mice and Humans” | Zendy

Eric L. Nuermberger | Zendy; Ian M. Rosenthal | Zendy; Rokeya Tasneen | Zendy; Charles A. Peloquin | Zendy; Khisimuzi Mdluli | Zendy; Petros C. Karakousis | Zendy; J Grosset | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reply to “Contradictory Results with High-Dosage Rifamycin in Mice and Humans”

Author(s) -

Eric L. Nuermberger,

Ian M. Rosenthal,

Rokeya Tasneen,

Charles A. Peloquin,

Khisimuzi Mdluli,

Petros C. Karakousis,

J Grosset

Publication year - 2013

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02216-12

Subject(s) - rifamycin , biology , pharmacology , antibiotics , computational biology , virology , medicine , microbiology and biotechnology

We thank Coates and colleagues for their interest in our recent paper demonstrating in two pathologically distinct murine models of tuberculosis (TB) that rifapentine (RPT) is approximately 4 times more potent (on a mg/kg body weight basis) than rifampin (RIF) when used alone and in combination with

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research